Watch CEROW. Know when insiders buy.
One email the day a filing lands. Free.
CEROW
CERO THERAPEUTICS HOLDINGS, INC.
No price history available
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
50
WATCH · shorts 50
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP —P/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$16.3MNET CASH $726K52W —SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$3.8M | −$1M | — | -0.70 | −$7.9M | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$4.8M | −$5.9M | — | -0.20 | $2.8M | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | — | −$4.5M | — | — | — | — | — | Apr 15 |
| Q3 2025 · Sep 30 | — | — | — | −$4.4M | −$4.9M | — | -9.10 | — | — | — | Nov 19 |
| Q2 2025 · Jun 30 | — | — | — | −$4.7M | −$5.4M | — | -61.71 | — | — | — | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$5M | −$5.1M | — | -31.82 | — | — | — | Aug 14 |
| Q3 2024 · Sep 30 | — | — | — | −$4.4M | −$4.2M | — | -170.22 | — | — | — | Nov 19 |
| Q2 2024 · Jun 30 | — | — | — | −$5.1M | −$2.4M | — | -302.32 | — | — | — | Nov 19 |
| Q4 2023 · Dec 31derived | — | — | — | −$1.1M | −$1.3M | — | -1247.97 | −$187K | — | — | Apr 15 |
| Q3 2023 · Sep 30 | — | — | — | −$1.5M | −$1.3M | — | -0.15 | −$256K | — | — | Nov 20 |
| Q2 2023 · Jun 30 | — | — | — | −$2.4M | −$2.1M | — | -0.23 | −$883K | — | — | Aug 14 |
| Q1 2023 · Mar 31 | — | — | — | −$2.4M | −$2.4M | — | -0.27 | −$198K | — | — | May 17 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | — | −$19.9M | — | — | −$16.1M | — | — | — | $127K |
| FY2023 · to Dec 31 | — | — | −$7.7M | −$7.3M | — | -1248.64 | −$1.5M | — | — | $33.5M | — |
| FY2022 · to Dec 31 | — | — | −$2.9M | −$668K | — | — | −$1.1M | — | — | $139.4M | — |
Every number comes from CERO THERAPEUTICS HOLDINGS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.